Home › NDC Lookup › Ingredients › Olopatadine › 70069-0017-01
👁️image loading
(from DailyMed)

Olopatadine 1 mg/mL Solution/ Drops

by Somerset Therapeutics, LLC · 1 BOTTLE, PLASTIC in 1 CARTON (70069-017-01) / 5 mL in 1 BOTTLE, PLASTIC
NDC 70069-0017-01
🏷️ FDA NDC (as labeled) 70069-017-01 billing pads the product segment with a zero
OTC Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 70069-017-01
Product NDC 70069-017
11-digit billing NDC 70069001701
NCPDP billing unit ML — per mL (volume)
RxCUI 1111339
UNII 2XG66W44KF
Application # ANDA206306
SPL Set ID 55142e80-c5db-46a5-85a5-e8a040bcc8cf
Established class (EPC) Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer
Mechanism of action Histamine H1 Receptor Antagonists
Physiologic effect Decreased Histamine Release
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-04-15
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance OLOPATADINE HYDROCHLORIDE
GPI-14 86802065102020
GCN Seq No 030796
GCN 68321
HICL code 012815
Ingredient (HICL) Olopatadine Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6R
Therapeutic class — specific (HIC3) Eye Antihistamines
AHFS code 52:02.00.00
AHFS class Antiallergic Agents
FDB label name OLOPATADINE HCL 0.1% EYE DROP
FDB brand name Olopatadine Hcl
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 70069-017-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70069-0017-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Histamine-1 Receptor Inhibitor class.

Pharmacologic class Histamine-1 Receptor Inhibitor, Histamine-1 Receptor Antagonist, Mast Cell Stabilizer
Drug family (ATC) Antiallergic agents, excl. corticosteroids, Other antiallergics
How it works Histamine H1 Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSomerset Therapeutics, LLC
Application holderSOMERSET THERAPEUTICS LLC
FDA applicationANDA206306 (ANDA)
Labeler code70069
First marketedApr 2024
Product typeHuman Otc Drug
Portfolio182 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name OLOPATADINE HCL 0.1% EYE DROP Ingredient Olopatadine Hcl
📗 Our plain-language guide HelloPharmacist
  • It does both, but with different products. The eye drops are for allergy-related itchy and red eyes. The nasal spray — brands like Patanase — is for seasonal allergic rhinitis, mea...
  • What exactly does olopatadine treat — is it just for eyes, or can it help my runny nose too?
  • You need to take your contacts out before you put the drops in. Wait at least 10 minutes after using the drops before you put them back in. Also, don't wear contacts at all if your...
  • Can I wear my contact lenses while using olopatadine eye drops?
📖 Read our full Olopatadine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Olopatadine Hydrochloride — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Olopatadine Hydrochloride (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $1.268 $6.34 / 5 ml
Medicaid paysCMS SDUD · 12 mo $2.64 $13.19 / 5 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Feb 2026 May 2026 Aug 2026 $1.268 $1.203
▲ Up 2% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Eye Allergy Itch and Redness Relief 1 mg/mL 70000-0054-01 CARDINAL 1 bottle $1.221 — Availability likely save 4%
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00536-1308-40 Rugby 1 bottle $1.223 — Discontinued save 4%
Olopatadine Hydrochloride 1 mg/mL 00536-1445-40 RUGBY 1 bottle $1.268 — Availability likely —
olopatadine hydrochloride 1 mg/mL 16571-0882-05 Rising 5 ml $1.268 — Availability likely —
Olopatadine Hydrochloride Ophthalmic 1 mg/mL 43598-0765-07 Dr. 1 bottle $1.268 — Availability likely —
Olopatadine Hydrochloride 1 mg/mL 46122-0672-64 Amerisource 1 bottle $1.268 — Availability likely —
Leader Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 70000-0717-01 CARDINAL 1 bottle $1.268 — Availability likely —
Olopatadine 1 mg/mLthis 70069-0017-01 Somerset 1 bottle $1.268 — Availability likely —
Olopatadine Hcl 1 mg/mL 70512-0520-05 Sola 1 bottle $1.268 — Availability likely —
Eye Allergy Itch and Redness Relief 1 mg/mL 70677-1156-01 Strategic 1 bottle $1.268 — Availability likely —
Olopatadine Hydrochloride 1 mg/mL 70677-1280-01 Strategic 1 bottle $1.268 — Availability likely —
Pataday Twice A Day Relief 1 mg/mL 00065-4274-01 Alcon 1 bottle $2.482 — Availability likely +96%
Olopatadine Hydrochloride 1 mg/mL 62332-0501-05 Alembic 1 bottle $3.065 — FDA listed +142%
Olopatadine Hydrochloride 1 mg/mL 00363-0200-40 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00363-0867-01 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00363-7130-05 Walgreens 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 11673-0689-05 Target 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 11822-0064-01 RITE 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 11822-9976-05 Rite 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 24208-0966-01 Bausch 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 30142-0064-64 Kroger 1 bottle — — FDA listed —
Eye Allergy Itch and Redness Relief Twice Daily Relief 1 mg/mL 43598-0826-07 Dr. 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 46122-0823-29 AmerisourceBergen 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 46708-0709-05 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 50090-6341-00 A-S 1 bottle — — FDA listed —
Olopatadine 1 mg/mL 50090-7959-00 A-S 1 bottle — — FDA listed —
Olopatadine hydrochloride 1 mg/mL 51407-0663-05 Golden 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 51407-0938-05 Golden 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution Twice Daily 1 mg/mL 55910-0109-05 DOLGENCORP, 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 58602-0006-40 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 58602-0009-40 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 58602-0012-40 Aurohealth 1 bottle — — FDA listed —
Olopatadine hydrochloride 1 mg/mL 60505-6221-00 Apotex 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 62332-0709-05 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 63868-0822-05 Chain 1 bottle — — FDA listed —
olopatadine hydrochloride ophthalmic 1 mg/mL 68083-0477-01 Gland 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 69168-0480-02 Allegiant 2 bottles — — FDA listed —
CVS Eye Allergy Itch Relief Twice Daily 1 mg/mL 69842-0268-05 CVS 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 72036-0008-40 Harris 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 72476-0852-64 Retail 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 72657-0168-50 GLENMARK 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 76162-0020-40 TOPCO 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 79481-1000-01 Meijer 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 79903-0000-40 Wal-Mart 1 bottle — — FDA listed —
Equate Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 79903-0319-01 WAL-MART 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 82442-0966-01 TARGET 1 bottle — — FDA listed —
Olopatadine Hydrochloride 1 mg/mL 85766-0111-05 Sportpharm 1 bottle — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2024
On the market since
Apr 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 70069-0017-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
120.9K
Units reimbursed last 4 qtrs
641.2K
Gross reimbursed last 4 qtrs
$1.69M
Avg / prescription
$13.98
Avg / unit
$2.6375
Latest quarter Q4 2025
30.3KRx
Medicaid pays / mL
$2.6375
gross reimbursed
vs
NADAC / mL
$1.2677
acquisition cost
=
Spread
+$1.3698
+108% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
63% FFS 37% MCO
Fee-for-service · 76,100 Rx Managed care · 44,841 Rx
State Medicaid map
Alaska: 915 units · 125 per 100k residents AK Maine: 1,850 units · 133 per 100k residents ME Washington: no data reported WA Idaho: 2,540 units · 129 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 33,730 units · 588 per 100k residents MN Wisconsin: 12,410 units · 210 per 100k residents WI Michigan: 27,925 units · 278 per 100k residents MI New York: 116,176 units · 594 per 100k residents NY Vermont: 1,095 units · 169 per 100k residents VT New Hampshire: 435 units · 31.0 per 100k residents NH Oregon: 3,060 units · 72.3 per 100k residents OR Nevada: 3,300 units · 103 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 55 units · 0.4 per 100k residents IL Indiana: 6,902 units · 101 per 100k residents IN Ohio: 47,743 units · 405 per 100k residents OH Pennsylvania: 38,951 units · 301 per 100k residents PA New Jersey: 7,920 units · 85.3 per 100k residents NJ Massachusetts: no data reported MA California: 227,314 units · 583 per 100k residents CA Utah: no data reported UT Colorado: 7,175 units · 122 per 100k residents CO Nebraska: 4,515 units · 228 per 100k residents NE Missouri: 7,050 units · 114 per 100k residents MO Kentucky: 7 units · 0.2 per 100k residents KY West Virginia: no data reported WV Virginia: 7,098 units · 81.4 per 100k residents VA Maryland: 3,113 units · 50.4 per 100k residents MD Connecticut: 7,515 units · 208 per 100k residents CT Rhode Island: 1,410 units · 129 per 100k residents RI Arizona: 5,560 units · 74.8 per 100k residents AZ New Mexico: 1,075 units · 50.9 per 100k residents NM Kansas: 4,830 units · 164 per 100k residents KS Arkansas: no data reported AR Tennessee: 10,279 units · 144 per 100k residents TN North Carolina: 10,030 units · 92.6 per 100k residents NC South Carolina: no data reported SC Delaware: 4,430 units · 430 per 100k residents DE Oklahoma: no data reported OK Louisiana: 5,900 units · 129 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 776 units · 7.0 per 100k residents GA D.C.: 485 units · 71.4 per 100k residents DC Hawaii: 1,730 units · 121 per 100k residents HI Texas: 22,008 units · 72.2 per 100k residents TX Florida: 3,850 units · 17.0 per 100k residents FL
Units reimbursed · per 100k residents
0.2594
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 594 /100k
2 Minnesota 588 /100k
3 California 583 /100k
4 Delaware 430 /100k
5 Ohio 405 /100k
6 Pennsylvania 301 /100k
7 Michigan 278 /100k
8 Nebraska 228 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Olopatadine — the ingredient across all brands.

Top reported reactions

Treatment Failure2,513
Device Delivery System Issue703
Drug Dose Omission By Device520
Eye Irritation349
Headache343
Nausea288
Fatigue280

Age at onset

Neonate1
Child46
Adolescent58
Adult803
Elderly452

Reporter sex

10,462 reports

Serious outcomes

Hospitalization1,649
Death341
Life-threatening252
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 2,800 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
70069-0017-01 You're viewing this 1 BOTTLE, PLASTIC in 1 CARTON (70069-017-01) / 5 mL in 1 BOTTLE, PLASTIC 2024-04-15 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 16 words ▾

Use temporarily relieves itchy and red eyes due to pollen, ragweed, grass, animal hair and dander

⏱️ Dosage and Administration 61 words ▾

Directions adults and children 2 years of age and older: put 1 drop in the affected eye(s) twice daily, every 6 to 8 hours, no more than twice per day if using other ophthalmic products while using this product, wait at least 5 minutes between each product replace cap after each use children under 2 years of age: consult a doctor

⚠️ Warnings 121 words ▾

Warnings For external use only Do not use if solution changes color or becomes cloudy if you are sensitive to any ingredient in this product to treat contact lens related irritation When using this product do not touch tip of container to any surface to avoid contamination remove contact lenses before use wait at least 10 minutes before reinserting contact lenses after use do not wear a contact lens if your eye is red Stop use and ask a doctor if you experience: eye pain changes in vision increased redness of the eye itching worsens or lasts for more than 72 hours Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 12 words ▾

Other information only for use in the eye store between 4°-25°C (39°-77°F)

🧪 Inactive Ingredients 19 words ▾

Inactive ingredients benzalkonium chloride 0.01%, dibasic sodium phosphate, hydrochloric acid/sodium hydroxide (adjust pH), sodium chloride and water for injection

🎯 Purpose 16 words ▾

Drug Facts Active Ingredients Purpose Olopatadine (0.1%) (equivalent to olopatadine hydrochloride 0.111%) Antihistamine and Redness Reliever

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 70069-0014-10 · Somerset 70069-0018-25 · Somerset →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.